Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA V "Wish List" From Consumers Union Includes Comparative Effectiveness Standard

This article was originally published in The Pink Sheet Daily

Executive Summary

Formally at the user fee negotiation table for the first time, the advocacy group wants new drugs to be tested against the "best practice" for treating a disease.

You may also be interested in...



PDUFA V Discussions To Begin With April 12 Meeting

FDA asks participants to focus on user fee processes and funding, not policy.

PDUFA V Discussions To Begin With April 12 Meeting

FDA asks participants to focus on user fee processes and funding, not policy.

FDA Will Review Need For New Laws On Drug Promotion

Strategic risk communications plan notes that agency will assess need for "additional legislation or regulation."

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel